Amgen Again Challenges Colo. Price Cap For Arthritis Drug
By Hailey Konnath · October 31, 2025, 10:37 PM EDT
Amgen has once again sued Colorado over its price cap for the arthritis drug Enbrel, claiming that the Centennial State's drug price-control statute violates the U.S. Constitution, conflicts with federal patent...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login